Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Vemurafenib-induced DRESS.

× No keyword cloud information.

11 in total

Review 1. Cutaneous toxicities of new treatments for melanoma.

Authors: A Boada; C Carrera; S Segura; H Collgros; P Pasquali; D Bodet; S Puig; J Malvehy
Journal: Clin Transl Oncol Date: 2018-05-24 Impact factor: 3.405

2. [Treatment side effects and follow-up of malignant melanoma].

Authors: T Stahl; C Loquai
Journal: Radiologe Date: 2015-02 Impact factor: 0.635

Review 3. Management of the cutaneous adverse effects of antimelanoma therapy.

Authors: Rose Congwei Liu; Germana Consuegra; Pablo Fernández-Peñas
Journal: Melanoma Manag Date: 2017-11-22

4. Vigabatrin-Induced Encephalopathy; Fidaxomicin Hypersensitivity Reactions; Vemurafenib-Induced DRESS; Severe Alkalosis and Hypokalemia With Stanozolol Misuse; Isotretinoin-Associated Lip Abscess; Eltrombopag-Associated Hyperpigmentation.

Authors: Michael A Mancano
Journal: Hosp Pharm Date: 2014-05

Review 5. Managing the skin toxicities from new melanoma drugs.

Authors: John C Mavropoulos; Timothy S Wang
Journal: Curr Treat Options Oncol Date: 2014-06

6. [Cutaneous side effects of anti-tumor therapy with BRAF and MEK inhibitors].

Authors: R Gutzmer; J C Hassel; K C Kähler; C Loquai; R Mössner; S Ugurel; L Zimmer; Für Komitee Kutane Nebenwirkungen Ado der das Ado
Journal: Hautarzt Date: 2014-07 Impact factor: 0.751

7. Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma.

Authors: N Kramkimel; A Thomas-Schoemann; L Sakji; Jl Golmard; G Noe; E Regnier-Rosencher; N Chapuis; E Maubec; M Vidal; Mf Avril; F Goldwasser; L Mortier; N Dupin; B Blanchet
Journal: Target Oncol Date: 2016-02 Impact factor: 4.493

Review 8. Potentially life‑threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review).

Authors: Emily L Coleman; Brianna Olamiju; Jonathan S Leventhal
Journal: Oncol Rep Date: 2020-12-24 Impact factor: 3.906

9. Successful use of dabrafenib after the occurrence of drug rash with eosinophilia and systemic symptoms (DRESS) induced by vemurafenib.

Authors: Camille Pinard; Claire Mignard; Agnès Samain; Anne-Bénédicte Duval-Modeste; Pascal Joly
Journal: JAAD Case Rep Date: 2017-11-06

Review 10. Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies.

Authors: Chun-Bing Chen; Ming-Ying Wu; Chau Yee Ng; Chun-Wei Lu; Jennifer Wu; Pei-Han Kao; Chan-Keng Yang; Meng-Ting Peng; Chen-Yang Huang; Wen-Cheng Chang; Rosaline Chung-Yee Hui; Chih-Hsun Yang; Shun-Fa Yang; Wen-Hung Chung; Shih-Chi Su
Journal: Cancer Manag Res Date: 2018-05-17 Impact factor: 3.989